Hamptons Center for Regenerative Medicine Review: What Its GLP-1 Documentation Establishes

A clinical trial can establish evidence for a studied medicine without establishing the performance of a business selling access to treatment. That distinction is central to Hamptons Center for Regenerative Medicine. Its website advertises compounded injectable semaglutide and tirzepatide, along with a GLP-1 Microdose program positioned around metabolic health and body composition. The practical question is not simply whether these ingredient names appear in research, but what the documentation establishes about the actual preparation, clinical service and ongoing arrangement a patient would receive.

Public pages consulted October 19, 2026, describe clinician review, partner compounding pharmacies, home delivery and continuing support. They also contain meaningful differences concerning cancellation, geographic availability and privacy. This documentary review separates those business claims from clinical evidence, without treating missing information as proof of poor care. No treatment was purchased, and the available documents do not independently establish the identities or credentials of the participating clinicians and pharmacies, the quality of a dispensed preparation, or patient outcomes within this program.

At a glance

Advertised injectable prices: Compounded semaglutide injection starts at $139 per month and tirzepatide injection at $149 per month, subject to provider review. The duration of those starting rates is not established.
Sources: [10] [11]
Business responsibility: Hamptons Longevity LLC owns the website and describes itself contractually as a technology platform, not a clinical provider or dispensing pharmacy.
Sources: [8]
Compounded-product disclosure: Treatment pages acknowledge that compounded medications are not FDA approved and that FDA has not independently verified their safety, efficacy and quality.
Sources: [11]
Cancellation conflict: The homepage says “Cancel anytime,” terms require disabling auto-refill at least 48 hours before processing, and treatment FAQs require 30 days’ notice.
Sources: [10] [8] [11]
Microdose uncertainty: The GLP-1 Microdose description does not establish its specific active ingredient, administration route or program price.
Sources: [7]

Start with the product, not the ingredient’s reputation

Hamptons offers access to compounded medication prepared by partner pharmacies, rather than documenting a program exclusively dispensing FDA-approved branded products. Its treatment pages say practitioners may prescribe customized formulations when commercially available treatments do not meet an individual patient’s needs. They also explicitly acknowledge the lack of FDA approval for compounded medications. Those disclosures matter: an ingredient name alone does not establish that a particular preparation has undergone the same review as an approved product.

FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Compounded preparations do not undergo FDA premarket review for safety, effectiveness and quality. Nonapproval alone, however, does not demonstrate clinical inequivalence or validate or condemn this platform. Our guide to approved medicines and compounded preparations explains why product approval and provider reliability are separate evidence questions.

The available documentation does not identify the dispensing pharmacies by name or establish the exact formulation a particular patient would receive. It therefore cannot independently verify those pharmacies’ licenses or connect an offered preparation to product-specific clinical research. The site describes access to independent, U.S. board-certified clinical providers and state-licensed compounding pharmacies; those remain provider representations here, not credentials independently checked for this review.

Different documents answer different questions
Documented item	What it establishes	What it does not establish
Injectable treatment listings	Access advertised for semaglutide and tirzepatide	Results for the actual compounded preparation
Compounding disclosure	The products are not FDA approved	Categorical equivalence or inequivalence
Clinical trial publications	Findings for the studied products and populations	Hamptons-specific patient outcomes
Microdose program description	The program’s advertised positioning	Its ingredient, route or demonstrated efficacy
Delivery description	Temperature-controlled packaging is promised	The condition of an individual shipment

Sources: [10] [11] [1]

Clinical research is not a Hamptons performance report

STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes, over 68 weeks. SURMOUNT-1 studied subcutaneous tirzepatide in adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. Neither was a trial of Hamptons Center for Regenerative Medicine, its partner pharmacies or its compounded products. The studies cannot establish this program’s effectiveness, service quality or likelihood of success for an individual.

Both trials also included tolerability findings, particularly gastrointestinal adverse effects, rather than only weight-change results. Novo Nordisk funded STEP 1, and Eli Lilly funded SURMOUNT-1. Those details belong alongside efficacy claims when evaluating the research. The trials were not a randomized head-to-head comparison, so comparing their headline percentages would not justify ranking Hamptons’ two offerings. Our explanation of why trials are not company performance reports addresses that distinction.

The separate GLP-1 Microdose offering requires an additional evidentiary boundary. Hamptons describes it as a lower-dose protocol for metabolic health, body composition and appetite recalibration, rather than aggressive weight loss. It markets the program to people near goal weight, those who poorly tolerated standard GLP-1 dosing, and people combining it with hormone or peptide plans. Those descriptions establish the intended audience, not clinical effectiveness; the consulted description does not identify the active ingredient, route or specific price.

Sources: [7] [2] [3]

The brand and the clinical provider are not interchangeable

The website presents Hamptons as a physician-led longevity practice providing weight loss, hormones, peptides, IV therapy and regenerative care through Long Island services and telehealth. Its terms describe a more divided operating structure. Hamptons Longevity LLC owns and operates the domain but says it acts solely as a technology platform connecting users with independent third parties. It expressly disclaims practicing medicine, providing clinical care, preparing or dispensing medication, or controlling professional judgment.

Those descriptions are not necessarily incompatible, but they answer different questions. The marketing describes the experience under the brand; the terms allocate responsibilities among the platform, medical group and pharmacy. Before enrolling, a reader should obtain the treating clinician’s identity, the responsible medical group’s name and the dispensing pharmacy’s name. Without those details, the public documentation does not let this review independently confirm who would assess the patient, prescribe the medication or handle a dispensing concern.

The business also advertises hormone optimization, peptide therapy, individualized IV infusions, body contouring, facial rejuvenation and regenerative therapies including stem cells, exosomes and PRP. Their appearance alongside GLP-1 treatment does not establish a shared evidence base or validate combined treatment. This review assesses the documented GLP-1 access arrangement, not the effectiveness of those additional services or the broader longevity positioning.

Sources: [4] [8] [11]

What the assessment and follow-up process promises

Enrollment begins with a short online assessment covering health goals and basic medical history. The homepage says a licensed clinician reviews it and creates a plan only if clinically appropriate. Treatment pages also offer an evaluation at the Long Island office and say a licensed physician reviews and authorizes the consultation. These descriptions do not promise a prescription. They also do not establish how quickly a clinical review occurs or whether every applicant receives a live appointment.

The semaglutide and tirzepatide pages publish screening criteria of adulthood, with BMI of 27 or higher, or 25 or higher with weight-related conditions. These are the provider’s stated criteria, not individualized eligibility findings or a substitute for product-specific assessment. The tirzepatide page lists exclusions including personal or family history of medullary thyroid carcinoma or MEN 2; pregnancy, breastfeeding or planned pregnancy; and active pancreatitis or untreated severe gastrointestinal disease.

Hamptons says its team reviews history, laboratory results and goals, but the consulted pages do not specify required tests, testing intervals or laboratory charges. Ongoing care includes structured check-ins and direct messaging through a secure portal, while the homepage says follow-ups occur as needed. No universal appointment frequency or clinical response deadline is established. Our guide to clinical follow-up beyond renewal notices explains why the actual care schedule deserves its own questions.

Sources: [10] [11] [5]

The starting price is documented; its duration is not

The homepage advertises semaglutide injection from $139 per month and tirzepatide injection from $149 per month. It also displays $249 and $299, respectively, without explaining those figures’ function in the consulted price blocks. The general starting price is subject to provider review. The pages do not establish whether the lower prices are introductory, how long they apply, what quantity accompanies a payment or what later charges might be. They should not be read as guaranteed treatment-long rates.

The injectable listings include a prescription, discreet home delivery and ongoing check-ins and support. Treatment pages advertise flat-rate pricing with no hidden fees, consultation charges or dose-change surcharges. The terms describe a bundled payment covering pharmacy medication charges, medical-group services and platform access. These are meaningful inclusion claims, but the laboratory question remains unresolved. A written quote should identify the actual product, formulation, presentation, quantity and included services rather than merely repeat the starting monthly figure.

Hamptons advertises “$0 if you’re not approved,” free 2–3 day shipping and no insurance requirement. That does not establish insurance acceptance, reimbursement paperwork, HSA/FSA acceptance or coverage by a particular plan. For recurring monthly orders, the terms authorize an immediate charge and another every 30 days until cancellation, with electronic notice five to seven days before a scheduled transaction. A 30-day billing interval is more specific than the homepage’s monthly shorthand and should guide questions about renewal dates.

Sources: [10] [11] [8]

Cancellation needs a product-specific written answer

The most consequential contractual discrepancy involves stopping recurring charges. The homepage advertises “Cancel anytime.” The terms say users may cancel by switching off auto-refill in the portal at least 48 hours before the applicable monthly processing date. Treatment FAQs instead require 30 days’ notice before the next billing cycle. Those are materially different deadlines. The documentation does not resolve which rule controls a particular enrollment, so this review cannot responsibly select the more favorable one.

A useful prepayment question is therefore concrete: which cancellation deadline applies to this exact program, where is that rule recorded, and how is cancellation confirmed? The answer matters because recurring charges begin immediately under the terms and continue every 30 days. The reminder arriving five to seven days before renewal would not, by itself, satisfy a 30-day notice requirement. That is a practical inconsistency to resolve before relying on an upcoming reminder.

Cancellation also does not establish refund eligibility. Treatment FAQs say consultations, medical visits and fulfilled prescriptions are nonrefundable once services begin or medication is processed. The advertised $0 charge for applicants who are not approved does not erase that separate boundary after services or medication processing have begun. The consulted documentation does not establish a broader money-back guarantee, nor does it establish a minimum commitment or a discounted prepayment arrangement.

Sources: [10] [8] [11]

Delivery claims leave pharmacy and timing questions

Hamptons describes partner-pharmacy preparation, shipment on a structured cadence, and temperature-controlled, unmarked packaging delivered to the home. The terms assign shipment directly to the applicable pharmacy. The advertised free 2–3 day shipping should not be treated as the full interval from assessment to receipt: clinical review, prescription authorization and pharmacy preparation have no established public turnaround here. Nor does a promised packaging method verify the temperature or condition of an individual delivery.

Pharmacy choice is restricted. The terms say purchasing a service or product that includes a prescription entails waiving the right to have it filled at a pharmacy of the patient’s choice. They also state that prescription products will not be dispensed in child-resistant containers. These provisions deserve attention before payment, particularly for readers expecting an outside pharmacy or child-resistant packaging. The available pages do not identify which partner pharmacy would fill a particular order.

FDA advises not using an injectable GLP-1 medication that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy to resolve the concern. FDA has also received reports of measuring or administration errors involving compounded medication, some associated with hospitalization. Those reports do not establish a Hamptons-specific event rate. Instructions should be clarified with the prescriber or pharmacist, not calculated from a review; our guide to cold-chain and delivery claims provides additional context.

Sources: [10] [11] [8] [1]

Access, contact and privacy require narrower readings

The homepage’s “Telehealth nationwide” language is broader than the terms, which restrict service to states where the company operates. Users must be at least 18, or the local age of majority if higher, and physically located in the same state as their recorded shipping address during consultation. No complete state or product-specific availability list is established. A traveler or prospective patient should therefore confirm actual location-based access rather than treat the national advertising as confirmation.

The contact page lists Hamptons Longevity LLC at 89 Forest Road, Centereach, NY 11720, telephone (631) 496-1102 and info@hamptonslongevity.center. Clinical hours are Monday through Friday, 9 a.m. to 5 p.m.; the displayed block does not specify a time zone. The form promises a team response within 24 hours, not clinical authorization, medication preparation or delivery within that period. Spanish-language care, interpretation and other-language clinical materials are not established in the consulted documentation.

Privacy language also varies. Treatment FAQs say medical information goes only to the physician and dispensing pharmacy and broadly state that data are never sold or shared. The terms say the platform is not a HIPAA-covered entity, although it may act as a business associate. A California notice permits certain advertising-related disclosures that may count as a sale or sharing under state law. These provisions concern different categories and roles, but the broad reassurance does not explain those distinctions adequately.

Sources: [10] [8] [9] [11] [6]

Questions & answers

Does Hamptons document FDA-approved GLP-1 products?

The reviewed offerings describe compounded medication, and treatment pages acknowledge that these preparations are not FDA approved. That is different from saying the ingredient has never been studied. It is also not proof that every compounded preparation is clinically inequivalent. Ask which exact product and formulation would be prescribed, why an approved product would not meet the identified need, and which pharmacy would prepare it.

Sources: [11] [1]

Is $139 or $149 the complete ongoing price?

Those are advertised starting monthly prices for semaglutide injection and tirzepatide injection, respectively, subject to provider review. The site claims bundled, flat-rate pricing without consultation or dose-change charges. However, the duration of the starting rates, supplied quantity, laboratory costs and meaning of the additional displayed $249 and $299 figures remain unresolved. Obtain the actual recurring charge and included services in writing.

Sources: [10] [11] [8]

Can I cancel 48 hours before renewal?

The terms describe cancellation by disabling portal auto-refill at least 48 hours before monthly processing, but treatment FAQs require 30 days’ notice before the next billing cycle. Because both statements appear in the public documentation, the shorter deadline should not be assumed to govern every program. Request a written product-specific answer. Separately, cancellation does not reverse the stated nonrefundability of services already begun or medication already processed.

Sources: [8] [11]

What is actually known about GLP-1 Microdose?

Hamptons positions Microdose as a lower-dose longevity-oriented protocol for metabolic health, body composition and appetite recalibration, including people near goal weight or with poor prior tolerance of standard programs. The consulted description does not establish its active ingredient, route or price. Research on studied semaglutide and tirzepatide regimens does not establish results for this offering. Request the product details and evidence supporting the specific proposed protocol.

Sources: [7] [2] [3]

Can I use my own pharmacy?

The terms restrict that choice for purchases including a prescription: they say users waive the right to fill it at a pharmacy of their choosing. The applicable partner pharmacy ships directly to the patient. Before purchasing, ask for its identity, contact information, the preparation being supplied and the process for reporting a shipment problem. The consulted pages do not identify the pharmacy assigned to an individual order.

Sources: [8]

Who can confirm state access and care arrangements?

The published contact paths are (631) 496-1102 and info@hamptonslongevity.center, plus the website inquiry form. Ask whether the exact program is available where you will physically be during consultation and where medication will ship. Also request the treating clinician’s identity and follow-up arrangements. The advertised 24-hour form response is a general team-response promise, not a clinical-review deadline or assurance of a prescription.

Sources: [9] [8] [10]

Our assessment

Hamptons documents a recognizable access model: clinical assessment, compounded injectable offerings, partner-pharmacy shipment, portal messaging and recurring bundled payments. Its explicit compounding disclosures and published starting prices are useful. The documentation is less conclusive about the exact preparation, named care partners, Microdose evidence, laboratory requirements and long-term price. Conflicting cancellation deadlines are especially important to resolve before payment, while broad national-access and privacy statements need their contractual qualifications. Clinical research supports conclusions about the products and regimens actually studied, not a verified outcome claim for this platform. A practical next step is to request a written product-and-service summary identifying the clinician, pharmacy, formulation, recurring charge, follow-up schedule and applicable cancellation rule. Clear answers would improve decision preparation; they would not substitute for individualized clinical assessment.

Visit Hamptons Center for Regenerative Medicine’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Hamptons Center for Regenerative Medicine Review: What Its GLP-1 Documentation Establishes

At a glance

01Start with the product, not the ingredient’s reputation

02Clinical research is not a Hamptons performance report

03The brand and the clinical provider are not interchangeable

04What the assessment and follow-up process promises

05The starting price is documented; its duration is not

06Cancellation needs a product-specific written answer

07Delivery claims leave pharmacy and timing questions

08Access, contact and privacy require narrower readings